Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) has provided an announcement.
Zai Lab Limited has filed preliminary proxy materials with the U.S. Securities and Exchange Commission for its 2025 annual general meeting. The agenda includes the re-election of directors, approval of auditor appointments, and authorization for the board to manage share allotments and repurchases. This filing is a regulatory step towards the annual meeting, reflecting Zai Lab’s commitment to corporate governance and shareholder engagement.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on developing and commercializing innovative therapies for oncology, autoimmune, and infectious diseases. The company is listed on the Hong Kong Stock Exchange and operates with a global market focus.
YTD Price Performance: 1.64%
Average Trading Volume: 400
Technical Sentiment Signal: Hold
Current Market Cap: €2.84B
See more data about 9688 stock on TipRanks’ Stock Analysis page.